# Shanghai Minwei Biotechnology Co., Ltd trials: 21 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with Shanghai Minwei Biotechnology Co., Ltd as lead sponsor, 10 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Shanghai Minwei Biotechnology Co., Ltd: 21 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 6 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/shanghai-minwei-biotechnology-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 10
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 17, 2026 | NCT07824804 | Phase 1 Clinical Study of MWN117 Injection in Healthy Participants and Participants With Obesity | Shanghai Minwei Biotechnology Co., Ltd | Phase 1 | Not yet recruiting | Healthy Volunteers, Obesity | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07824804) |
| September 4, 2026 | NCT07804810 | Phase 2 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity | Shanghai Minwei Biotechnology Co., Ltd | Phase 2 | Completed | Overweight , Obesity | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07804810) |
| September 4, 2026 | NCT07804797 | Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or Obesity | Shanghai Minwei Biotechnology Co., Ltd | Phase 2 | Active not recruiting | Overweight , Obesity | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07804797) |
| September 4, 2026 | NCT07803835 | Phase 1 Clinical Study of MWX401 Injection in Chinese Healthy Participants and Participants With Mild Hypertension | Shanghai Minwei Biotechnology Co., Ltd | Phase 1 | Recruiting | Essential Hypertension, Healthy Volunteers | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07803835) |
| September 4, 2026 | NCT07803822 | Phase 2 Clinical Study of MWX203 Injection Alone or in Combination With Inclisiran Sodium Injection in Patients With Mixed Dyslipidemia | Shanghai Minwei Biotechnology Co., Ltd | Phase 2 | Recruiting | Mixed Dyslipidemia | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07803822) |
| September 4, 2026 | NCT07803809 | Phase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity | Shanghai Minwei Biotechnology Co., Ltd | Phase 1 | Recruiting | Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07803809) |
| September 3, 2026 | NCT07801820 | Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus | Shanghai Minwei Biotechnology Co., Ltd | Phase 2 | Recruiting | Type 2 Diabetes Mellitus (T2DM) | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801820) |
| September 3, 2026 | NCT07801326 | A Study to Evaluate Different Administration Conditions and the Food Effect of MWN109 Tablets in Chinese Participants | Shanghai Minwei Biotechnology Co., Ltd | Phase 1 | Completed | Type 2 Diabetes Mellitus (T2DM), Overweight , Obesity | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801326) |
| September 3, 2026 | NCT07801313 | Phase 1 Clinical Study of MWN105 Injection in Healthy Chinese Volunteers | Shanghai Minwei Biotechnology Co., Ltd | Phase 1 | Completed | Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801313) |
| September 2, 2026 | NCT07799025 | Phase 1 Clinical Study of MWX203 Injection in Healthy Subjects | Shanghai Minwei Biotechnology Co., Ltd | Phase 1 | Active not recruiting | Healthy Volunteers | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07799025) |
| August 28, 2026 | NCT07791654 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in... | Shanghai Minwei Biotechnology Co., Ltd | Phase 2 | Completed | Overweight , Obesity | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791654) |
| August 28, 2026 | NCT07791537 | Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight | Shanghai Minwei Biotechnology Co., Ltd | Phase 2 | Active not recruiting | Overweight , Obesity | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791537) |
| August 28, 2026 | NCT07791524 | Phase 2 Study of MWN109 Tablet in Participants With Overweight or Obesity | Shanghai Minwei Biotechnology Co., Ltd | Phase 2 | Completed | Overweight , Obesity | 255 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791524) |
| August 26, 2026 | NCT07787728 | Phase Ib Clinical Study of MWN109 Injection in Participants With Overweight or Obesity | Shanghai Minwei Biotechnology Co., Ltd | Phase 1 | Completed | Overweight , Obesity | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07787728) |
| August 26, 2026 | NCT07787624 | Phase 1 Clinical Study of MWN109 Injection in Healthy Chinese Volunteers | Shanghai Minwei Biotechnology Co., Ltd | Phase 1 | Completed | Healthy Volunteers | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07787624) |
| August 26, 2026 | NCT07787611 | Phase I Clinical Study of MWN109 Tablets in Healthy Chinese Participants | Shanghai Minwei Biotechnology Co., Ltd | Phase 1 | Completed | Healthy Volunteers | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07787611) |
| August 21, 2026 | NCT07779980 | Phase 1 Clinical Study of MWN110 Injection in Healthy Participants and Overweight or Obese Participants | Shanghai Minwei Biotechnology Co., Ltd | Phase 1 | Not yet recruiting | Overweight , Obesity | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07779980) |
| August 21, 2026 | NCT07778693 | Phase 3 Study of MWN109 Injection in Participants With Overweight or Obesity | Shanghai Minwei Biotechnology Co., Ltd | Phase 3 | Not yet recruiting | Overweight , Obesity | 760 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778693) |
| June 8, 2026 | NCT07634510 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWX205 | Shanghai Minwei Biotechnology Co., Ltd | Phase 1 | Not yet recruiting | Dyslipidemias | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634510) |
| April 22, 2025 | NCT06938269 | A Study to Evaluate MWN109 Tablets in Healthy Adult Participants | Shanghai Minwei Biotechnology Co., Ltd | Phase 1 | Recruiting | Overweight or Obesity | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06938269) |
| March 5, 2025 | NCT06859853 | A Study to Evaluate MWN109 Injection in Healthy Subjects | Shanghai Minwei Biotechnology Co., Ltd | Phase 1 | Recruiting | Overweight or Obese | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06859853) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 13 |
| Phase 2 | 7 |
| Phase 3 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 8 |
| Recruiting | 6 |
| Not yet recruiting | 4 |
| Active not recruiting | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Obesity | 14 |
| Overweight | 13 |
| Diabetes Mellitus, Type 2 | 4 |
| Dyslipidemias | 1 |
| Essential Hypertension | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Biotechnology companies in the United States](https://specstream.ai/data/businesses/biotechnology-companies/united-states)
- [Buffet restaurants in the United States](https://specstream.ai/data/businesses/buffet-restaurants/united-states)
- [Home automation companies in the United States](https://specstream.ai/data/businesses/home-automation-companies/united-states)
- [Prosthetics providers in the United States](https://specstream.ai/data/businesses/prosthetics-providers/united-states)
- [Auto insurance agencies in the United States](https://specstream.ai/data/businesses/auto-insurance-agencies/united-states)
- [Executive search firms in the United States](https://specstream.ai/data/businesses/executive-search-firms/united-states)
